|
CN101503461A
|
|
Polypeptide with liver cancer apoptosis reducing function
|
|
CN101481707A
|
|
Construction of tissue specific eucaryon expression vector pIE and use in HLA-DR transgenic technology
|
|
CN101455840A
|
|
Composite capable of strengthening anti-tumor immune response
|
|
CN101624622A
|
|
Kit for quantitatively detecting PML/RARalpha mRNA level
|
|
CN101624620A
|
|
Kit for quantitatively detecting AML1/ETO mRNA level
|
|
CN101381414A
|
|
Ovarian cancer anti-idiotype antibody and preparation of heat shock protein fusion protein and application
|
|
CN101244257A
|
|
Application of type II collagen allosteric peptide for treating rheumatoid arthritis with nasal mucosa medicine administration
|
|
CN101307304A
|
|
Anti-human ovarian carcinoma anti-anti-idiotype antibody hybridoma cell line, and monoclonal antibody and application thereof
|
|
CN101186635A
|
|
Application of M3 type receptor protein polypeptide resisting antibody measurement in Sjogren syndrome diagnosis
|
|
CN101062051A
|
|
Injection liquid for vitreous cutting operation and the preparing method thereof
|
|
CN101008004A
|
|
Use of liver cell line QSG-7701 for infecting hepatitis B virus
|
|
CN1872333A
|
|
Placenta factor, preparation method and application
|
|
CN1609203A
|
|
Human ovary carcinoma resisting monoclonal antibody hybridoma cell line and its monoclonal antibody and application
|
